Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICHARD B POWELL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1023103702
CMS profile
819362
Location
NEW PORT RICHEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,086.41

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,289.60 8
Food and Beverage $796.81 7

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ModernaTX, Inc. $1,656.40 5
Biogen, Inc. $1,413.37 9
Electromed, Inc. $16.64 1

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICHARD B POWELL

NPI 1023103702 · CMS profile ID 819362

Allopathic & Osteopathic Physicians / Internal Medicine

NEW PORT RICHEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023103702?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICHARD B POWELL, NPI 1023103702, CMS profile ID 819362. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023103702?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RICHARD B POWELL, NPI 1023103702, CMS profile ID 819362. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023103702?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RICHARD B POWELL, NPI 1023103702, CMS profile ID 819362, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1023103702?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $3,086.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Electromed, Inc. $16.6411/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 977386233 CMS
Biogen, Inc. $50.4010/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012143397 CMS
Biogen, Inc. $62.5510/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012152844 CMS
Biogen, Inc. $62.5510/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012234969 CMS
Biogen, Inc. $342.8410/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012234973 CMS
Biogen, Inc. $45.2310/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012256455 CMS
Biogen, Inc. $73.3310/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012275629 CMS
Biogen, Inc. $120.3310/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012188375 CMS
Biogen, Inc. $409.9010/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012237051 CMS
Biogen, Inc. $246.2410/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012271487 CMS
ModernaTX, Inc. $690.2101/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981513 CMS
ModernaTX, Inc. $40.0001/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981517 CMS
ModernaTX, Inc. $267.7101/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981521 CMS
ModernaTX, Inc. $247.4701/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981525 CMS
ModernaTX, Inc. $411.0101/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981529 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,998.99 5
PY2020 $39.93 2
PY2023 $3,086.41 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $123,379.85 19
PY2024 Principal investigator $519,613.32 181
PY2023 Principal investigator $3,705,517.67 2,390
PY2022 Principal investigator $2,801,811.98 590
PY2021 Principal investigator $422,228.81 39
PY2020 Principal investigator $83,061.46 21
PY2019 Principal investigator $408,254.19 140

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

181 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,869.76 12/21/2024 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1130970465
Principal investigator 1 Seqirus USA Inc $20,744.00 08/02/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123448785
Principal investigator 1 ModernaTX, Inc. $32,514.75 07/25/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147140564
Principal investigator 1 Seqirus USA Inc $1,088.00 07/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123448847
Principal investigator 1 Seqirus USA Inc $506.00 07/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123448849
Principal investigator 1 ModernaTX, Inc. $2,556.90 07/11/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147140556
Principal investigator 1 ModernaTX, Inc. $1,755.00 07/04/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147140548
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,856.00 06/26/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1110845044
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447281
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447283
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447285
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447287
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447289
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447291
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447293
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447295
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447297
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447299
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447301
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447303
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447305
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447307
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447309
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447311
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447313
Principal investigator 1 Seqirus USA Inc $506.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123447315
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448111
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448113
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448115
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448117
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448119
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448121
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448123
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448125
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448127
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448129
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448131
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448133
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448135
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448137
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448139
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448141
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448143
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448145
Principal investigator 1 Seqirus USA Inc $1,088.00 06/19/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 1123448147
Principal investigator 1 SWEDISH ORPHAN BIOVITRUM AB $1,000.00 05/29/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
SEL-212/301 No dispute reported 06/30/2026 1146417101
Principal investigator 1 SWEDISH ORPHAN BIOVITRUM AB $1,500.00 05/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
SEL-212/301 No dispute reported 06/30/2026 1146417103
Principal investigator 1 SWEDISH ORPHAN BIOVITRUM AB $1,200.00 05/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
SEL-212/301 No dispute reported 06/30/2026 1146417105
Principal investigator 1 SWEDISH ORPHAN BIOVITRUM AB $1,300.00 05/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
SEL-212/301 No dispute reported 06/30/2026 1146417107
Principal investigator 1 SWEDISH ORPHAN BIOVITRUM AB $1,000.00 05/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
SEL-212/301 No dispute reported 06/30/2026 1146417109
Principal investigator 1 SWEDISH ORPHAN BIOVITRUM AB $2,200.00 05/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
SEL-212/301 No dispute reported 06/30/2026 1146417111
Principal investigator 1 SWEDISH ORPHAN BIOVITRUM AB $1,828.00 05/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
SEL-212/301 No dispute reported 06/30/2026 1146417115
Principal investigator 1 SWEDISH ORPHAN BIOVITRUM AB $150.30 05/20/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
SEL-212/301 No dispute reported 06/30/2026 1146417113
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,145.00 04/26/2024 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1078938764
Principal investigator 1 ModernaTX, Inc. $33,561.00 04/17/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147132991
Principal investigator 1 Roche Diagnostics Operations, Inc. $13,428.86 04/10/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1125621665
Principal investigator 1 PFIZER INC. $5,000.00 03/28/2024 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1131050990
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,703.00 03/25/2024 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1078938756
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,500.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1078938760
Principal investigator 1 ModernaTX, Inc. $432.00 03/15/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147132541
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444392
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444394
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444396
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444398
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444400
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444402
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444404
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444406
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444408
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444410
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444412
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444414
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444416
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444418
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444420
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444422
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444424
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444426
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444428
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444430
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444432
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444654
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444656
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444658
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444660
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444662
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444664
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444666
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444668
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444670
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444672
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444674
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444676
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444678
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444680
Principal investigator 1 Seqirus USA Inc $506.00 03/15/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123444682
Principal investigator 1 ModernaTX, Inc. $897.75 03/08/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147132519
Principal investigator 1 ModernaTX, Inc. $59,399.06 03/08/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147132529
Principal investigator 1 ModernaTX, Inc. $1,053.00 03/08/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147132531
Principal investigator 1 ModernaTX, Inc. $1,255.50 03/08/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147132533
Principal investigator 1 ModernaTX, Inc. $243.00 03/08/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147132535
Principal investigator 1 ModernaTX, Inc. $688.50 03/08/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147132537
Principal investigator 1 ModernaTX, Inc. $20,906.10 03/08/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147132539
Principal investigator 1 Roche Diagnostics Operations, Inc. $81.00 02/09/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1125620880
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,750.00 01/31/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1110836483
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $100.00 01/27/2024 Non-covered Recipient Entity
Velocity Clinical Research Durham
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1101074719
Principal investigator 1 Roche Diagnostics Operations, Inc. $2,700.00 01/24/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1125620723
Principal investigator 1 ModernaTX, Inc. $127,179.74 01/16/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147140430
Principal investigator 1 Seqirus USA Inc $853.60 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123440598
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441048
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441366
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441368
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441370
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441372
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441374
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441376
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441378
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441466
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441468
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441470
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441472
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441474
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441476
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441478
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441480
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441482
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441484
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441486
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441488
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441490
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441492
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441494
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441496
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441498
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441500
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441526
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441528
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441530
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441532
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441534
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441536
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441538
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441540
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441542
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441544
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441546
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441548
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441550
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441552
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441554
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441556
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441558
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441560
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441562
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441564
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441566
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441568
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441570
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441572
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441574
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441576
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441578
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441580
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441582
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441584
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441586
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441588
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441590
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441592
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441594
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441596
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441598
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441600
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441602
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441604
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441606
Principal investigator 1 Seqirus USA Inc $587.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441608
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441610
Principal investigator 1 Seqirus USA Inc $1,088.00 01/12/2024 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1123441612
Principal investigator 1 ModernaTX, Inc. $37,800.00 01/05/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147131765
Principal investigator 1 Boehringer Ingelheim International GmbH $242.50 01/01/2024 Non-covered Recipient Entity
Velocity Clinical Research Cincinnati Blue Ash
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1101071955